[SCHEDULE 13G] VERTEX PHARMACEUTICALS INC / MA Passive Investment Disclosure (>5%)
Rhea-AI Filing Summary
Vertex Pharmaceuticals Inc Schedule 13G shows Vanguard Capital Management reported beneficial ownership of 19,036,076 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing discloses sole voting power for 2,523,266 shares and sole dispositive power for 19,036,076 shares. The form is signed by Ashley Grim on 04/30/2026 and includes affiliate attribution language describing managed accounts and Vanguard fund holdings.
Positive
- None.
Negative
- None.
Insights
Vanguard reports a sizable passive stake in Vertex (7.49%) as of 03/31/2026.
Vanguard Capital Management discloses beneficial ownership of 19,036,076 shares with sole dispositive power over that entire amount and sole voting power for 2,523,266 shares. The filing attributes holdings across Vanguard affiliates and managed funds per SEC Release No. 34-39538.
Because Schedule 13G typically reports passive investment positions, the filing indicates institutional scale but not an active control intent; subsequent filings would show any change in intent or active engagement.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
SEC Release No. 34-39538 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.